Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Liabilities (2016 - 2025)

Assembly Biosciences has reported Total Liabilities over the past 11 years, most recently at $50.8 million for Q4 2025.

  • Quarterly results put Total Liabilities at $50.8 million for Q4 2025, down 40.75% from a year ago — trailing twelve months through Dec 2025 was $50.8 million (down 40.75% YoY), and the annual figure for FY2025 was $50.8 million, down 40.75%.
  • Total Liabilities for Q4 2025 was $50.8 million at Assembly Biosciences, down from $57.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for ASMB hit a ceiling of $95.7 million in Q4 2023 and a floor of $9.9 million in Q3 2023.
  • Median Total Liabilities over the past 5 years was $31.0 million (2021), compared with a mean of $44.1 million.
  • Biggest five-year swings in Total Liabilities: plummeted 49.65% in 2022 and later surged 648.96% in 2024.
  • Assembly Biosciences' Total Liabilities stood at $22.1 million in 2021, then decreased by 13.56% to $19.1 million in 2022, then surged by 400.4% to $95.7 million in 2023, then dropped by 10.36% to $85.8 million in 2024, then tumbled by 40.75% to $50.8 million in 2025.
  • The last three reported values for Total Liabilities were $50.8 million (Q4 2025), $57.3 million (Q3 2025), and $62.7 million (Q2 2025) per Business Quant data.